Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder.

@article{Baldwin2012VortioxetineA,
  title={Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder.},
  author={David S. Baldwin and Thomas Folkmann Hansen and Ioana Florea},
  journal={Current medical research and opinion},
  year={2012},
  volume={28 10},
  pages={
          1717-24
        }
}
OBJECTIVE The primary objective of this study was to evaluate the safety and tolerability of the investigational drug vortioxetine (Lu AA21004) in the long-term treatment of patients with major depressive disorder. METHODS Patients entered this 52-week, open-label extension study after completing an 8-week lead-in study. Safety and tolerability were evaluated at regular intervals on the basis of spontaneously reported adverse events (AEs), clinical safety laboratory tests, vital signs, ECG… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 35 CITATIONS

Vortioxetine: A Review of Its Use in Major Depressive Disorder

VIEW 11 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Vortioxetine: First Global Approval

VIEW 6 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED